# US 5,352,679 A · Use of rifaximin and pharmaceutical formulations containing it in the treatment of gastric dyspepsia caused by helicobacter pylori

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,352,679 A
- Document ID: US5352679A
- Status: Granted
- Kind: A
- Application number: 08/083,453
- Filed: 1993-06-28
- Granted: 1994-10-04
- Earliest claimed: 1993-03-23
- Assignees: Alfa Wassermann S.p.A.
- Inventors: Antonella Ferrieri; Leone G. Rotini
- Web page: https://patentgrep.com/patent/US5352679A

## CPC

- A61K 31/44: Non condensed pyridines; Hydrogenated derivatives thereof
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The antibiotic known by the name rifaximin (INN) is active orally in the treatment of gastric dyspepsia caused by bacteria known as Helicobacter pylori. Rifaximin may be administered in any oral pharmaceutical form, particularly tablets, capsules, sugar coated tablets, granules and syrups containing from 200 to 2000 mg of active principle, at a daily dosage of between 400 and 2000 mg.

## Claims

### Claim 1

The method of treatment of a patient affected by gastric dyspepsias caused by Helicobacter pylori, which consists of orally administering to said patient a composition in unit dosage form containing rifaximin in the amount of 200-2000 mg per dose.

### Claim 2 (depends on 1)

The method according to claim 1 wherein said composition is in the form of a tablet, a capsule, a sugar coated tablet, granules or a syrup.

### Claim 3 (depends on 1)

The method according to claim 1 wherein the total daily dose of rifaximin is 400-2000 mgs.